Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE DX versus GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE DX versus GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.
DIMETANE-DX vs GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane-DX contains brompheniramine (first-generation antihistamine) and dextromethorphan (NMDA receptor antagonist and sigma-1 agonist). Brompheniramine antagonizes histamine at H1 receptors, reducing allergic symptoms; dextromethorphan suppresses cough by acting on the cough center in the medulla oblongata via NMDA receptor antagonism and sigma-1 receptor activation.
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.
Adults and children ≥12 years: One tablet (brompheniramine 4 mg, dextromethorphan 10 mg, phenylephrine 10 mg) orally every 4 hours as needed, not to exceed 4 doses in 24 hours.
For adults and children ≥12 years: 10 mL (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 mL (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.
None Documented
None Documented
Brompheniramine: 25-30 hours; guaifenesin: 1 hour; dextromethorphan: 2-4 hours (CYP2D6 extensive metabolizers) or 20-40 hours (poor metabolizers).
Guaifenesin: 1-2 hours; Dextromethorphan: 3-6 hours (extensive metabolizers), 18-24 hours (poor metabolizers due to CYP2D6 polymorphism).
Renal: 50-70% (brompheniramine) as metabolites and unchanged drug; guaifenesin metabolites primarily renal; dextromethorphan and metabolites renal. Biliary/fecal: minor.
Guaifenesin: ~60% renal (metabolites), ~35% fecal; Dextromethorphan: ~70% renal (parent and metabolites, 45% as unchanged dextrorphan), ~20% biliary/fecal.
Category C
Category C
Antitussive Combination
Expectorant/Antitussive Combination